Literature DB >> 35953729

Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study.

Mellar Davis1, Charles Loprinzi2.   

Abstract

Chemotherapy-induced neuropathy is difficult to manage, and the pain associated with neuropathy is poorly responsive to gabapentin in a randomized trial. Duloxetine is the only drug that has been found to be effective in reducing pain from chemotherapy neuropathy. In this qualitative review, the use of pregabalin for chemotherapy-induced neuropathy is discussed including the rationale and pharmacological reasons why pregabalin should be considered in a large, randomized placebo-controlled trial.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alpha2dellta; Calcium channel; Chemotherapy; Neuropathy; Pain; Pregabalin

Year:  2022        PMID: 35953729     DOI: 10.1007/s00520-022-07317-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.359


  101 in total

Review 1.  Chemotherapy-induced peripheral neuropathy.

Authors:  Stefan Quasthoff; Hans Peter Hartung
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

2.  The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.

Authors:  Natalie B Simon; Michael A Danso; Thomas A Alberico; Ethan Basch; Antonia V Bennett
Journal:  Qual Life Res       Date:  2017-06-29       Impact factor: 4.147

3.  Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial.

Authors:  Ebrahim Salehifar; Ghasem Janbabaei; Narjes Hendouei; Abbas Alipour; Nasim Tabrizi; Razieh Avan
Journal:  Clin Drug Investig       Date:  2020-03       Impact factor: 2.859

4.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

5.  Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.

Authors:  Cielito C Reyes-Gibby; Phuong Khang Morrow; Aman Buzdar; Sanjay Shete
Journal:  J Pain       Date:  2009-11       Impact factor: 5.820

Review 6.  Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.

Authors:  Christina Teng; Jordan Cohen; Sam Egger; Prunella L Blinman; Janette L Vardy
Journal:  Support Care Cancer       Date:  2021-08-19       Impact factor: 3.603

Review 7.  Chemotherapy-induced neuropathy.

Authors:  Anthony J Windebank; Wolfgang Grisold
Journal:  J Peripher Nerv Syst       Date:  2008-03       Impact factor: 3.494

8.  Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.

Authors:  Fiona Yeo; Chiu Chin Ng; Kiley W J Loh; Alex Molassiotis; Hui Lin Cheng; Joseph S K Au; Kwun To Leung; Yu Chung Li; Kam-Hung Wong; Lorna Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Aishwarya Bandla; Emily Ang; Violeta Lopez; Raghav Sundar; Alexandre Chan
Journal:  Support Care Cancer       Date:  2019-04-10       Impact factor: 3.603

9.  Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).

Authors:  Costantine Albany; Travis Dockter; Eric Wolfe; Jennifer Le-Rademacher; Nina Wagner-Johnston; Lawrence Einhorn; Jacqueline M Lafky; Ellen Smith; Deirdre Pachman; Nathan Staff; Cynthia Ma; Charles L Loprinzi; Brian A Costello
Journal:  Support Care Cancer       Date:  2020-06-04       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.